Patent · US Active

Universal donor cells

US11008587B2 · kind B2 · utility

6Cited by

25References

16Claims

0Family size

Assignee

CRISPR THERAPEUTICS AG · CH

Inventors

Alireza Rezania · Cambridge, US
Rebeca Ramos-Zayas · Cambridge, US

Key dates

Filing date	Jul 14, 2020
Grant date	May 18, 2021
Priority date	—
Expiry date	Jul 14, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/80
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.